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Abstract
Age-related macular degeneration (AMD) is one of the most common causes 
of severe visual loss in middle and old-age population, and often leads to serious 
deterioration in quality of life. Currently, the first-line treatment for neovascular 
AMD (nAMD) are intravitreal injections of anti-vascular endothelial growth factor 
(VEGF) medications, including bevacizumab, ranibizumab, and aflibercept and 
also latest commercially available drug, brolucizumab. During initial examination 
and imaging and treatment follow-up for patients with nAMD, optical coherence 
tomography (OCT) is used to predict and assess the therapeutic response and guide 
the treatment. Several OCT-based biomarkers, including the central subfoveal 
thickness (CSFT), the presence of intraretinal cysts (IRCs) or subretinal fluid 
(SRF), and the presence of pigment epithelial detachment (PED), were found to 
influence baseline visual acuity or visual improvements. Recent analyses of large 
randomized control trials (RCTs) summarized the usefulness of these OCT-based 
biomarkers. However, many of these early studies relied on time-domain OCT to 
evaluate the retinal structures thus providing less precise evaluation of the retinal 
details. After introduction of spectral-domain OCT (SD-OCT) which provided high 
resolution images, recent studies offered new insights in specific morphological 
changes and their different impact on visual function in nAMD. For example, these 
advancement in resolution offered new classification of IRCs into degenerative and 
exudative which impacts treatment strategy and final outcome in the treatment of 
nAMD. Moreover, the recent data disclose a substantial difference between RCTs 
and real-world studies regarding the response to anti-VEGF therapy. In conclusions, 
IRCs and PED are associated with poor visual improvement in nAMD in a realworld 
setting. Both IRCs and SRF responded better than PED to anti-VEGF therapy. These 
observations mandate large longitudinal studies focusing on the usefulness of these 
high resolution SD-OCT biomarkers in real-world situations.
Keywords: Anti-VEGF treatment, biomarkers, intraretinal cysts, intraretinal fluid, 
neovascular AMD, OCT, pigment epithelial detachment, subretinal fluid
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1. Introduction
Improving or maintaining visual acuity is the main target of treatment of neo-
vascular age-related macular degeneration (nAMD). Standard nAMD care mandate 
frequent intravitreal (IVT) antivascular endothelial growth factor (VEGF) injec-
tions, which represents a heavy burden on patients, health systems, and physicians.
Age-related macular degeneration (AMD) is the leading cause of blindness in 
developed countries, with a global prevalence of 8.69% [1]. The prevalence of AMD 
increases with age among all ethnicities and in all geographic regions, as a result of a 
growing aging population [2].
Age-related macular degeneration is a progressive, chronic, multifactorial 
disease of the retina that can lead to visual impairment and blindness, mostly 
affecting individuals aged more than 60 years [3]. The disease progresses from early 
to advanced stages and can be divided into 2 major advanced forms: neovascular 
(wet) AMD (nAMD) and geographic atrophy in dry AMD [4]. A smaller proportion 
of patients with AMD (20%) are diagnosed with nAMD, but it is responsible for 
the majority (90%) of vision loss cases and presents as acute painless loss of vision 
[5, 6]. Neovascular AMD is characterized by the presence of choroidal neovascu-
larization (CNV), a pathologic form of angiogenesis resulting in leakage of fluid 
that accumulates in the retina, subretinally or below the retinal pigment epithelium 
(RPE); other features include the development of RPE tears, hard exudates, hemor-
rhage, or fibrous disciform scar tissue formation [7–9].
These clinical abnormalities in patients with nAMD lead to a gradual loss of 
retinal photoreceptors, resulting in decreased vision and even blindness if disease 
progression is not prevented [10].
Central vision is the key to variuos daily activities, including a person’s ability 
to read, drive, and recognize faces [11]. The loss of central vision that accompanies 
AMD greatly affects an individual’s quality of life [12].
Deleterious effect of vision loss on an individual’s quality of life mandates 
further development of effective treatment modalities and new molecules to 
treat nAMD.
2. Advances in nAMD treatment
Preservation of visual function is the main goal for nAMD treatment. This is 
achieved by inhibition of the new blood vessel growth and reduction of the fluid 
leakage [13]. Vascular endothelial growth factor is a major molecule which contrib-
utes to development of CNV [14]. Choroidal neovascularization can be slowed by 
inhibiting VEGF binding to its receptor, VEGF receptor-2, on blood vessels, which 
is the major proangiogenic pathway [15]. Anti-VEGF agents are antibodies which 
neutralize VEGF binding to its receptor and they have different mechanisms of 
action. They reduce fluid leakage from the CNV, stop growth, and lead to regres-
sion of CNV [16]. The introduction of the anti-VEGF drugs into clinical practice 
has immensely improved the prognosis for patients with nAMD, in such a way that 
nAMD is no longer considered an incurable disease [17]. The first anti-VEGF agent 
approved in 2004 by Food and Drug Administration (FDA) was pegaptanib sodium, 
an aptamer that binds VEGF₁₆₅ [18]. Ranibizumab, an antibody fragment that binds 
all VEGF-A isoforms was FDA approved in 2006 after the ANCHOR and MARINA 
studies [19, 20]. In the following years, from 2006 till 2013, there were 2 other 
anti-VEGF therapies available for nAMD treatment: aflibercept and conbercept, 
approved based on the results of the VIEW 1 and VIEW 2 studies, and PHOENIX 
study, respectively [21, 22]. Both of them are antibody fusion proteins [23].
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Two other anti-VEGF agents approved for therapy in oncology are used “off-
label” for nAMD: ziv-aflibercept and bevacizumab [7]. Current care standards for 
nAMD include regular intravitreal (IVT) injections of anti-VEGF therapy [24]. This 
poses a substantial burden on patients, as well as health systems worldwide [3]. For 
some patients, anti-VEGF treatment involves monthly injections over a long period 
of time, making patient adherence and monitoring difficult, which in turn has 
consequences for visual and anatomic outcomes [25]. Also, the cost associated with 
managing nAMD is substantial [26]. In an attempt to lessen the load of frequent 
therapy and costs associated with anti-VEGF medications, some clinicians proposed 
alternative dosing strategies which are different from those in the registered clinical 
trials (q4- or q8-weeks). These include pro re nata (PRN) and treat-and-extend 
(TAE) regimens [27]. They attempt to provide the same efficacy and at the same 
time more convenient regimen that is easier to adhere to and is taking into account 
individual OCT features of the patient.
Brolucizumab, a newly developed anti-VEGF drug for nAMD treatment, has 
demonstrated longer durability and improvement in visual and anatomic outcomes 
in clinical studies in a q12-week regimen, indicating its potential to reduce treat-
ment burden as an important therapeutic tool in nAMD management [28].
3. The role of OCT + OCT-A in nAMD
3.1 Specific OCT biomarkers
Several OCT-based biomarkers, including the central subfoveal thickness 
(CSFT), the presence of intraretinal cysts (IRCs) or fluid (IRF), subretinal fluid 
(SRF), and sub-RPE fluid or pigment epithelial detachment (PED), were found 
to be associated with baseline visual acuity and response to the anti-VEGF treat-
ment (Figure 1). One of the main goals in the management of nAMD has been the 
removal of fluid in the macular compartments [26]. The clinical significance of 
fluid depends on its location where it plays a major role in determining the long 
term success of the treatment and its presence should be recorded at baseline, 
according to the guidelines from the Vision Academy. Fluid segments should be 
assesed individually and fluid status evaluated after loading phase and throughout 
the course of treatment [29, 30].
The introduction of OCT into everyday clinical practice allowed a new clas-
sification of CNV according to its location, complementing fluorescein angiography 
(FA) and indocyanin green angiography (ICGA) [31]. In OCT, type 1 CNV, located 
between Bruch membrane (BM) and RPE, corresponds to PED, often accompanied 
Figure 1. 
OCT biomarkers.
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by subretinal fluid and in later stages of disease by IRC [32]. Type 2 CNV presents 
as subretinal hyperreflective material (SHRM) and shows concomitant IRF and SRF 
[33]. SHRM may be composed of exudative fluid, fibrin, blood, or scarring and its 
characteristics may change during treatment period [34]. According to CATT study, 
SHRM was present in 77% of treatment-naive eyes at baseline with the prevalence 
decreasing to 58% at week 4 after treatment and further to 46% after 2 years [35]. 
It is hypothesized to be caused probably by a dehydration and condensation of the 
active CNV component [36, 37].
IRC overlying PED, accompanied by SRF, are typical features commonly present 
in retinal angiomatous proliferation (RAP), classified as type 3 CNV by Freund 
et al. [38]. Mature type 3 lesions, associated with serous PEDs, are highly responsive 
to anti-VEGF therapy [39]. However, the development of GA has frequently been 
described in association with treatment of RAP lesions [40].
3.1.1 Central subfoveal thickness
The greatest importance of CSFT was actually in the research because it was 
used as a criterion for continued treatment in trials of various drugs and treatment 
protocols. If the reduction in CSFT after injection is less than 25%, this is consid-
ered a criterion for reinjection [41, 42].
Value of CSFT depends mostly on the amount of retinal fluid in the different 
retinal compartments, so in most cases a higher CSFT is also a sign of a worse VA. If 
the cause of CSFT is mostly retinal fluid, it will be reduced by treatment with anti-
VEGF factors, and VA in this case will be better or not get worse. Recently there was 
an observation that there is a direct correlation between vision, fluid, the amount of 
fluid, and fluctuations in CST [28]. A new option is to look at what effect a drug has 
on fluctuations in CST, which may prove to be extremely important in identifying 
patients at risk for closer monitoring and more aggressive therapy.
The presence of an epiretinal membrane (ERM) and the accumulation of 
drusenoid or fibrous material may also be responsible for a higher CSFT. In this 
case, the prognosis for CSFT reduction with anti-VEGF treatment is usually 
poor [28, 41].
A certain percentage of subjects in clinical trials as well as patients in clini-
cal practice developed geographic atrophy (GA) after treatment with anti-VEGF 
factors. Risk factors for such development include the presence of foveal fluid and 
monthly dosing of injections. In the CATT study, approximately 38% of subjects 
developed GA after 5 years, mainly those receiving ranibizumab rather than afliber-
cept. In the case of GA development, a lower CSFT will also mean a significantly 
lower VA [7, 43].
3.1.2 Intraretinal fluid
Intraretinal fluid appears as round or oval hyporeflective spaces – cysts, but may 
also present as diffuse thickening of the neurosensory retina [1]. Intraretinal cysts 
(IRCs) are OCT biomarkers for various retinal diseases such as nAMD, diabetic 
macular edema, central retinal vein occlusion, and uveitic macular edema.
Since IRCs often differ in their shape and size, and also in their response to anti-
VEGF therapy, some authors have divided them into exudative and degenerative. 
The criteria taken into account were the size of the cyst, its shape, and the possible 
alteration of the continuity of the RPE below the cyst. Degenerative cysts were 
described as smaller than 125 μm, usually square in shape and with RPE altera-
tions below the cyst itself, while exudative cysts are more often ovoid and larger 
[41, 44, 45]. Intraretinal fluid usually results from active fluid exudation, but the 
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degenerative cysts may orginate from passive fluid accumulation due to atrophy of 
neurosensory elements [1]. Exudative cysts had better initial response to 3 loading 
monthly injections of anti-VEGF treatment whereas degenerative cysts had lower 
response to the therapy, persisted for a longer time and were associated with lower 
VA after treatment [44–47].
3.1.3 Subretinal fluid
Subretinal fluid can be characterized as hyporeflective fluid accumulation 
overlying the RPE layer. It resolves in most eyes in response to anti-VEGF treatment, 
however, not as rapidly as IRF.
According to the several studies, the presence of SRF at baseline or after 1-year 
treatment did not significantly affect VA [44, 48, 49]. Residual SRF may not 
always represent ongoing neovascular activity. It may instead be dysfunction of 
the RPE leading to SRF accumulation, much like central serous chorioretinopathy 
[50, 51]. Among patients treated with a PRN regimen, those who presented with 
SRF achieved even higher VA gains [52]. VA was stable regardless of treatment 
frequency [53]. The pathomechanism for the beneficial role of SRF has not been 
fully explained but possible explanations suggest the preservation of photoreceptor 
integrity, less IRF, RPE atrophy and fibrosis [54].
3.1.4 Pigment epithelial detachment
Pigment epithelial detachment (PED) (Figure 2) the anatomical separation of 
the RPE from the Bruch membrane i.e. sub-RPE fluid is present in about 30–80% of 
nAMD patients based on the CATT, EXCITE, and VIEW studies [41, 55, 56].
PED lesions have been classified based on clinical findings, angiography and 
OCT assessment (height, width, greatest linear diameter, area, volume, reflectivity, 
progression and response to treatment of PED lesions) [57]. Three subtypes of PED 
may be identified based on the reflectivity of the material under the RPE: serous 
(primarily hyporeflective; hollow), solid (primarily hyperreflective; drusenoid), 
and mixed (combination of solid and serous PEDs; fibrovascular) [58–60]. The 
CNV membrane itself corresponds to hyperreflective material along the back 
surface of the PED, readily visible by enhanced-depth imaging, or a tomographic 
notch within the PED, identifiable by conventional OCT [61].
PED has a negative effect on VA only in combination with additional com-
ponents, mostly IRF [47, 62]. In VIEW studies, the baseline presence of PED, 
disrupted external limiting membrane (ELM) and ellipsoid zone (EZ), and greater 
CSFT were associated with poor baseline VA [46]. However there are some contro-
versial data by real-world study where initial VA was worse and visual improvement 
Figure 2. 
Pigment epithelial detachment.
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poorer if PED was present before treatment regardless of IRC or SRF presence 
[44]. Microperimetry analysis has shown higher retinal sensitivity for SRF and 
serous PED (sPED) than for IRF and fibrovascular PED (fvPED) [63]. The volume 
of fvPED at baseline was associated with impaired VA and PED growth seemed to 
precede fluid recurrence [64–66].
When SRF is located on the top of a PED (rather than on its edge), without 
associated IRF, hemorrhage, then probably the PED is not vascularized and will 
response poorely to anti-VEGF therapy [67]. PEDs are also less responsive to anti-
VEGF treatment than SRF or IRC in nAMD [41, 46]. Serous PEDs showed better 
response to IVIs than fibrovascular ones which may suggest that they are possible 
signs of lesion activity. Serous PEDs showed most improvement in VA whereas 
fvPEDs showed most reduction in PED height, especially with aflibercept [50, 57, 
68–70]. Fibrovascular PEDs may be difficult to treat, but even these eyes can gain 
vision with anti-VEGF therapy. The IVIs change PED morphology in such way that 
their content becomes more hyperreflective, suggesting an increasing fibrovascular 
maturization of the CNV [71]. PEDs behavior and functional outcomes are influ-
enced by the treatment regimen. VIEW trials found that the switch from a monthly 
to an as-needed regimen led to reactivation of PED with a resultant decline in visual 
outcome, especially in patients who developed secondary IRC following that change 
[46]. The recurrence of PED is the primary event of neovascular activation [47].
Treatment should focus on vision gains rather than PED resolution because 
there is no apparent correlation between anatomical and functional improvement 
in most eyes with PED and nAMD. More frequent anti-VEGF doses may improve 
anatomical response, without correlation with vision improvement [29]. Atrophy 
may complicate eyes with PED and nAMD after anti-VEGF therapy, especially in 
association with complete PED resolution [29].
In 15–20% of eyes with PEDs a RPE tear that may lead to decline or loss of 
vision spontaneously but also as a serious complication of anti-VEGF therapy. 
Hyperreflective lines in near-infrared (NIR) images and PEDs greater than 500 μm 
to 600 μm in height on OCT present an indicator of an increased risk in develop-
ing an RPE tear in eyes where the sub-RPE CNV has created contractile folds in 
response to the treatment [72, 73]. RPE tears after anti-VEGF therapy only devel-
oped in patients with serous PED (14.6%) [74].
In conclusion, the presence or persistence of a PED may still be compatible with 
relatively good visual acuity, but may require more regular treatment.
3.2 Specific OCT-A biomarkers
Noninvasive OCT angiography (OCT-A) generates images of the retinal and 
choroidal vessels, with the excellent sensibility and specificity for detection of the 
CNV compared to FA and ICGA [75, 76]. OCT-A provides detailed visualization of 
the CNV complex in patients with nAMD and its evolution in response to anti-
VEGF treatment, disclose a perfused vascular network in nonexudative stage of 
CNV and also in advanced cases of evident nAMD with fibrotic scars and history of 
prior treatment with anti-VEGF therapies [77]. CNV type 1 and 2 seem to be more 
easily visualised on OCT-A compared with retinal angiomatous proliferation (RAP) 
or polypoidal lesions [78].
Current studies evaluate the association between OCT-A parameters, structural 
OCT changes and functional response on anti-VEGF therapies. Five qualitative cri-
teria have been recognized on OCT-A: (1) Numerous branching capillaries between 
major vessels separating the lesion area into fractals, (2) end-to-end anastomoses 
or intervascular anastomoses within the lesion, (3) arcades or vascular loops at 
the vessel termini, (4) major, well-defined filamentous vessels, and (5) peri- or 
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intralesional nonvascularized hypointense halos surrounding or embedding the 
CNV membrane [75]. Greater rate of small branching vessels and peripheral arcades 
have been detected in immature lesions and a dead-tree appearance in hypermature 
lesions [79]. A qualitative classification algorithm has been developed based on 
neovascular density as a predictive factor for clinical activity [80]. Recently, some 
authors have demonstrated quantitative biomarkers for nAMD disease activity: (1) 
CNV’s blood flow surface area (SA), (2) vessel density (VD), (3) fractal dimension 
(FD), and (4) lacunarity index (LAC) [81].
Blood flow SA is a readily available and well-studied OCT-A parameter. Previous 
qualitative assessments of OCT-A images in CNV networks showed that most of the 
lesions demonstrated shrinkage of fine peripheral vessels and arteriogenesis of the 
remaining vessels after anti-VEGF treatment [82]. The branching complexity and 
blood flow area decrease after the loading doses then regrow and return to the origi-
nal size at 12 months irrespective of the treatment protocol. The same modifications 
of blood flow area in patients followed under PRN and TAE regimens [83]. SA also 
seems to have a weak association with functional outcomes (i.e. VA), highlighting 
the need to assess other parameters. Finally, the baseline blood flow area had an 
inverse association with the number of IVIs concerning baseline FD [83].
FD quantifies branching pattern complexity and organization of the vascular 
structure. It varies according to the number of secondary divisions of the CNV: the 
higher the number of discernible secondary divisions, the higher the FD value [84]. 
Many authors demonstrated attenuation and pruning of secondary ramifications after 
anti-VEGF treatments, with subsequent decrease of the FD value. A FD values is lower 
in the inactive stage than in the active stage [83, 84]. A weak association between 
blood flow aspect (FD) and retinal fluid suggests that factors other than CNV 
morphology are responsible for retinal exudation [79]. There is a poor association 
between the most studied quantitative OCT-A parameters and functional outcomes at 
12 months’ follow-up. FD did not differ between good and bad responders [83].
Lacunarity (LAC) is a measure of the size of gaps within a structure. Higher 
values reflect heterogenic texture of vascular networks and lower values reflect a 
more homogeneity of vascular skeleton. The results showed that arrangement of 
lacunas of the vascular plexus do not change after anti-VEGF, therefore lacunarity 
may be an OCT-A parameter for nAMD follow-up [85].
According to some investigators, patients with a lower baseline FD and a lower SA 
have higher odds of having 8 or more IVI injection during the first year. Typical exam-
ples of patients that required less than 8 IVI in the first year of treatment are large and 
complex CNVs. On the other hand, typical examples of patients that required more 
than eight IVI in the first year of treatments are small lesions with a disorganized 
architecture [83]. A hypothesis is that in the presence of high VEGF levels, CNVs 
would have numerous tiny branches and a disorganized architecture, reflecting an 
aggressive angiogenic process with greater exudation and a heavier treatment burden. 
In eyes with lower VEGF availability, CNV would grow without leakage maturing 
their branching architecture toward a complicated network before exudation becomes 
overly symptomatic [86]. In conclusion, it seems that all evaluated OCT-A parameters 
were poor biomarkers in predicting anatomic and functional response but baseline 
FD and SA were the best biomarkers regarding treatment burden.
4. The role of visual acuity on long term prognosis
Early response to anti-VEGF therapy has been shown to be an important 
predictor of VA recovery in nAMD treatment. VA after 3 months of consecutive 
intravitreal injections is a better prognostic factor than baseline VA [87]. Likewise, 
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early morphological change of the described OCT biomarkers is a very important 
prognostic factor for overall treatment outcome.
Thus, early accurate monitoring of treatment responses by analysis of OCT 
findings and VA is of great importance to optimize the number of injections during 
treatment in achieving the goal of vision function recovery.
5. Conclusions
Introduction of OCT into everyday clinical practice has revolutionized diag-
nosis and management of nAMD. This diagnostic tool has pivotal role in terms of 
disease monitoring and evaluation of treatment efficacy. Many studies give hope 
that in the future we will be able to offer a better or possibly individual approach to 
the anti-VEGF treatment that will give the optimal morphological recovery of the 
macula and VA. The risk factors identified for persistent CNV activity may help 
clinicians to identify patients for closer monitoring and more aggressive therapy.
The main OCT features predictive of persistent disease activity are IRCs, SRF, 
sPED recurrence, and those indicative of poorer VA outcome are IRCs, large extent 
of SHRM damage to the photoreceptor or RPE layer [35]. Exudative IRCs have been 
shown to require monthly treatment, in particular after recurrence of PED [37, 88]. 
Patients with IRC after 12 monthly IVIs have shown a higher risk for fibrosis and 
RPE atrophy compared with patients presenting refractory SRF [89]. By contrast, 
SRF is associated with stable VA, regardless of treatment frequency, and with better 
visual gain [50, 51, 90, 91]. Consequently, SRF is an ideal feature for identifying 
patients suitable for flexible or treat and extend regimens.
By contrast, SRF is associated with stable VA, regardless of treatment frequency, 
and with better visual gain, and consequently, is an ideal for flexible or treat and 
extend regimens [50, 51, 90, 91]. In conclusion, these subtypes tell us what out-
comes we are hoping to achieve. We can personalize the treatment to some extent 
– treatment intervals can be maintained or extended where disease inactivity is 
achieved, i.e. IRF is improving or SRF is stable, or more agressive or in shortened 
intervals in patients with new and/or increased fluid. It is postulated that persistent 
IRF should never be tolerated whereas with persistent SRF we are less likely to treat 
until dry [92]. Advisably is also identifying patients with fluctuations in CSFT, who 
are convenient for closer monitoring and more aggressive therapy [28].
OCT-A may differentiate active CNV lesions from stable fibrous complexes 
which could be relevant for treatment decisions. Quantitative OCT-A parameters 
have shown as poor biomarkers in predicting anatomic and functional response 
although blood flow area and FD are slightly better than the others.
Recently, automated quantification algorithms have been proposed for the 
analysis of OCT images with CNV, namely multi-resolution graph-theoretic-based 
surface detection for PED segmentation and machine learning-based pixel clas-
sification for IRC and SRF segmentations [93]. Machine learning algorithms are 
particularly suitable for determining treatment effect after the loading phase 
[94]. Computational analysis of OCT images is expected to become even more 
widespread in the clinical treatment strategies. This will hopefully establish a set of 
standardized protocols that will allow personalized anti-VEGF treatments based on 
identifying important differences in retinal responses between patients.
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Abbreviations
VEGF vascular endothelial growth factor
AMD age-related macular degeneration
nAMD neovascular age-related macular degeneration
OCT optical coherence tomography
CSFT central subfoveal thickness
IRC intraretinal cysts
SRF subretinal fluid
PED pigment epithelial detachment
sPED serous
fvPED fibrovascular
ELM external limiting membrane
EZ ellipsoid zone
RCT randomized control trials
SD-OCT spectral domain optical coherence tomography
IVT intravitreal
IVI intravitreal injection
CNV choroidal neovascularization
RPE retinal pigment epithelium
PRN pro re nata (as needed)
TAE treat-and-extend
ERM epiretinal membrane
GA geographic atrophy
RAP retinal angiomatous proliferation
SHRM subretinal hyperreflective material
NIR near-infrared
OCT-A optical coherence tomography angiography
SA surface area
VD vessel density
FD fractal dimension
LAC lacunarity index
FAZ foveal avascular zone
FA fluorescein angiography
IVGA indocyanin green angiography
BM Bruch membrane
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